Pathogenicity and Epitope Characteristics of Anti-Desmoglein-1 from Pemphigus Foliaceus Patients Expressing Only IgG1 Autoantibodies  by Hacker-foegen, Mary K. et al.
ORIGINAL ARTICLE
Pathogenicity and Epitope Characteristics of Anti-Desmoglein-1
from Pemphigus Foliaceus Patients Expressing Only IgG1
Autoantibodies
Mary K. Hacker-Foegen, Marleen Janson, Masayuki Amagai,w Janet A. Fairley,z and Mong-Shang Lin
Department of Dermatology, Medical College of Wisconsin, and wthe Veteran A¡airs Medical Center, Milwaukee,Wisconsin, USA; wDepartment of
Dermatology, Keio University School of Medicine,Tokyo, Japan
Pemphigus foliaceus (PF) is an antibody-mediated
autoimmune disorder with IgG1 and IgG4 as the predo-
minant subclasses of autoantibodies against a desmoso-
mal glycoprotein, desmoglein-1 (Dsg1). Previously, we
found that the IgG4 anti-Dsg1 autoantibodies only re-
cognize a conformational epitope(s), whereas the IgG1
autoantibodies recognize both conformational and lin-
ear epitopes but do not display pathogenicity in the pas-
sive transfer animal model. The purpose of this study
was to analyze the epitopes recognized by autoanti-
bodies from a subset of PF patients who only express
anti-Dsg1 of the IgG1 isotype throughout the course of
their diseases and to further characterize the pathogeni-
city of their IgG1 anti-Dsg1. We found that IgG1 auto-
antibodies in this subset of PF patients, similar to IgG4
autoantibodies from other PF patients, are able to bind
both human and mouse skin and induce the experi-
mental PF in mice. Moreover, a detailed epitope map-
ping reveals that the conformational epitopes recog-
nized by IgG1 autoantibodies from these PF patients
are restricted to the ¢rst 161 amino acids of Dsg1,
whereas the linear epitopes are spread throughout the
entire ectodomain. In conclusion, our study reveals that
the isotype of IgG does not necessarily determine the
epitopes and pathogenicity of pemphigus autoantibo-
dies. J Invest Dermatol 121:1373 ^1378, 2003
P
emphigus foliaceus (PF) is an autoimmune cutaneous
disorder characterized by subcorneal blisters in the epi-
dermis and circulating autoantibodies that recognize
the desmosomal glycoprotein desmoglein-1 (Dsg1)
(Civatte, 1943; Lever, 1965; Wheeler et al, 1991; Buxton
and Magee, 1992). The target antigen, Dsg1, is a 160- kDa trans-
membrane protein and a member of the desmoglein subfamily of
the cell adhesion supergene family (Wheeler et al, 1991; Buxton
and Magee, 1992).The intracellular domain of Dsg1 interacts with
a desmosomal plaque component, plakoglobin, linking it to the
cytoskeleton (Korman et al, 1989), whereas its extracellular do-
main harbors disease-relevant epitopes and might mediate the
heterophilic interaction that brings about cell adhesion (Marcozzi
et al, 1998).
The subcorneal blisters in PF are formed by a process of kera-
tinocyte cell^cell detachment known as acantholysis. In active PF,
the Nikolsky’s sign is easily elicited (Lever, 1965). Unlike pemphi-
gus vulgaris, mucosal blisters or erosions are not observed in PF
patients. Recently, however, it was demonstrated by electron mi-
croscopy that several mucosal tissues exhibit signs of intercellular
space widening, suggesting the possible involvement of mucosae
in PF (Guedes et al, 2002). In pemphigus vulgaris, approximately
50% of patients carry IgG autoantibodies against Dsg1 in addi-
tion to anti-desmoglein-3 (Dsg3), whereas in PF, only 7% of pa-
tients show autoantibody activity against Dsg3 (Arteaga et al,
2002). Further autoantibody pro¢le analysis reveals that the pre-
dominant isotypes of anti-Dsg1 in PF patients are IgG4 and IgG1
( Jones et al, 1988; Futei et al, 2001; Warren et al, 2003), with the
titer of IgG4 closely associated with the activity of the disease,
while the IgG1 titer remains constant throughout the course of
the disease (Warren et al, 2003).
When evaluating the pathogenic activity of anti-Dsg1 subclass
autoantibodies using a passive transfer animal model, it was de-
monstrated that only the IgG4, but not IgG1, autoantibodies were
capable of inducing experimental PF (Rock et al, 1989). This result
led to a belief that the inability of IgG1 anti-Dsg1 to induce the
experimental PF is due to the lower titer or nonpathogenic activ-
ity of this subclass of autoantibodies or utilization of insu⁄cient
amounts of antibodies in the experiments. In light of our recent
¢ndings that contradict the common belief, it is now clear that
the inability of IgG1 anti-Dsg1 to induce experimental PF in neo-
natal mice is because this subclass of autoantibodies, although it
binds tissues from human skin and monkey esophagus, fails to
cross-react with murine epidermis (Hacker et al, 2002). Further-
more, we found that anti-Dsg1 of the IgG4 recognizes a confor-
mational epitope(s), while the IgG1 anti-Dsg1 in PF patients
recognizes both linear and conformational epitopes.
In this study, we identi¢ed a unique subset of PF patients (4 of
52) who only express IgG1 autoantibodies by direct and indirect
immuno£uorescence (IF) staining and ELISA. Similar to IgG4
autoantibodies from other PF patients, the IgG1 autoantibodies
from this subset of patients are able to reproduce the clinical,
immunologic, and histologic features of PF when injected into
neonatal mice. Using recombinant Dsg1/-3 domain-swapped
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proteins and competition ELISA, we further determined that the
conformational epitopes recognized by these IgG1 autoantibodies
are located in the ¢rst 87 amino acids of Dsg1, whereas the linear
epitopes are spread throughout the ectodomain of Dsg1. The
clinical and immunologic characterization of this group of pa-
tients further elucidates the complexity of autoimmunity in PF.
Both human and animal protocols in this study have been ap-
proved by the MCWand in adherence to the Helsinki Principles.
For human subject studies, we have obtained Exemption Four
Status in our approval in which, we do not have direct contact
with patients and are only allowed to use samples that will other-
wise be discarded.
MATERIALS AND METHODS
Serum samples Serum samples from 52 PF patients with active diseases
were obtained from the dermatology clinic at the Medical College of
Wisconsin. The diagnosis of PF was made on the basis of clinical
examination and biopsy as well as direct and indirect IF staining. This
study was approved by the Institutional Review Board of the Medical
College of Wisconsin.
Subclass direct and indirect IF staining Indirect IF was used to study
the binding of the patients’ autoantibodies to epidermal tissues from
di¡erent sources (Beutner and Jordon, 1964). In this study, monkey
esophagus, adult human skin from the thigh, and the dorsal skin of
neonatal BALB/c mice were used as substrates. For Ig subclass staining,
mouse anti-human IgG, IgG1, IgG2, IgG3, and IgG4 (Zymed
Laboratories, San Francisco, CA) were used as secondary antibodies. The
intercellular space staining pattern on the epidermal substrates was
visualized by sheep anti-mouse IgG conjugated with £uorescein (Zymed).
Subclass direct IF was performed by incubating perilesional skin from PF
patients with mouse anti-human IgG1, IgG2, IgG3, or IgG4 and sheep anti-
mouse IgG conjugated with £uorescein. The direct and indirect IF results
were documented using a SPOT digital camera (Diagnostic Instruments,
Inc., Sterling Heights, MI).
Preparation of recombinant desmoglein proteins Recombinant
proteins encompassing the extracellular domain of Dsg1 (rDsg1) and
Dsg3 (rDsg3) were prepared from a baculovirus expression system
with a stretch of six histidines engineered immediately downstream
of the recombinant proteins (Ding et al, 1999). The domain-swapped
proteins, Dsg31^161/Dsg1164^496, Dsg31^403/Dsg1404^496, Dsg11^161/Dsg3163^566,
Dsg11^401/Dsg3405^566, Dsg11^87/Dsg387^566, and Dsg31^88/Dsg189^496 were
constructed as described (Sekiguchi et al, 2001). These proteins were
puri¢ed by Ni-NTA column according the protocol provided by the
manufacturer (Qiagen, Chatsworth, CA).
Fragments spanning portions of Dsg1 were constructed as glutathione
S-transferase (GST) fusion proteins and expressed in the prokaryotic
system as described (Liu et al, 1995). In total, 11 fusion proteins were
produced and used in the study. The amino acid sequences of these
proteins are Dsg1.1, AA 1^60; Dsg1.2, AA 54^93; Dsg1.3, AA 80^156;
Dsg1.4, AA 137^199; Dsg1.5, AA 178^233; Dsg1.6, AA 213^278; Dsg1.7,
AA 264^309; Dsg1.8, AA 303^344; Dsg1.9, AA 337^401; Dsg1.10, AA
381^444; and Dsg1.11, AA 424^501.
Detection of subclass anti-Dsg1 autoantibodies by ELISA Circulat-
ing Dsg1 autoantibodies were identi¢ed by Dsg1 ELISA.The Dsg1 subclass
ELISAs were established according to previous publications except mouse
anti-human IgG, IgG1, IgG2, IgG3, or IgG4 conjugated with horseradish
peroxidase (HRP) (Zymed) were used as the secondary antibodies in this
study (Arteaga et al, 2002; Hacker et al, 2002).
To identify the conformational epitopes recognized by PF patients
expressing only anti-Dsg1 of the IgG1 isotype, a competition ELISA was
employed as previously described (Sekiguchi et al, 2001). Brie£y, serum
samples from PF patients were ¢rst preincubated with various
concentrations of Dsg-swapped proteins at room temperature for 1 h.
Subsequently, the activity of anti-Dsg1was assessed by ELISA.
Immunoblotting (IB) assays IB was performed as previously described
(Hacker et al, 2002). Brie£y, 200 ng of rDsg1, rDsg3, and GST fusion
proteins was resolved by SDS-PAGE, transferred to nitrocellulose (Gibco
BRL, Gaithersburg, MD), and incubated with the patients’ sera at a
dilution of 1:100. Secondary antibody, mouse anti-human IgG, IgG1,
IgG2, IgG3, and IgG4 conjugated with HRP (Zymed) was used at a
dilution of 1:1000. After a 15-h incubation with the primary antibody at
room temperature, blots were washed and then incubated for 2 h with
HRP^anti-human IgG antibodies. The anti-Dsg1 signal was visualized
by an enhanced chemiluminescence system (Amersham Biosciences,
Piscataway, NJ) according to the manufacturer’s protocol.
Induction of experimental PF by passive transfer experiments To
assess the pathogenic activity of the PF patients’ autoantibodies, the passive
transfer model was utilized (Arteaga et al, 2002). Brie£y, 100 mL of IgG
(protein G column puri¢ed) from two PF patients was administered to
neonatal BALB/c mice (1 mg/g body weight) by the intradermal route. In
the preabsorption experiments, autoantibodies from PF patients were ¢rst
incubated with equal quantity of rDsg1 or rDsg3 at room temperature for 1
h before injecting to neonatal BALB/c mice.The skins of the neonatal mice
were examined 18 h after the IgG injection, and signs of cutaneous disease
were recorded.The animals were then euthanized and skin specimens were
obtained from lesional sites for histologic examination by hematoxylin and
eosin staining and light microscopy. Fluorescein isothiocyanate-conjugated
goat anti-human IgG was obtained commercially (Kirkegaard & Perry
Laboratories, Gaithersburg, MD) and used to identify the deposits of PF
IgG in the mouse skin by direct IF.
RESULTS
IgG1 anti-Dsg1 is the sole subclass autoantibody in a subset
of PF patients To analyze the isotype pro¢le of the PF auto-
antibodies, ELISA and indirect IF microscopy were performed.
In a total of 52 PF patients with active disease, we found 4 who
expressed only anti-Dsg1 autoantibodies of the IgG1 isotype (not
shown). None of the 4 patients tested were positive for the
presence of anti-Dsg3 autoantibodies (not shown). By direct IF,
only IgG1 was detected in the perilesional skins from patients’
biopsies (not shown). There is no remarkable di¡erence in the
clinical expression of this subset of PF patients compared to
other PF patients seen in our clinics. In a series of samples
collected from these 4 patients over time, all tested positive only
for the presence of IgG1 anti-Dsg1 by ELISA (not shown). To
analyze the tissue speci¢city of autoantibodies from these
patients, indirect IF was performed using epithelial tissues from
monkey esophagus, adult human skin, and neonatal mouse skin.
As shown in Fig 1, only total IgG (Fig 1A,D,G) and IgG1 (Fig
1B,E,H), but not IgG4 (Fig 1C,F,I) and other isotypes (not
shown) of autoantibodies from these patients were able to stain
these three substrates. These results were concordant with the
¢nding that only IgG1, but no IgG2, IgG3, or IgG4,
autoantibody deposits were detected in the perilesional skin of
these patients by direct IF microscopy.
IgG1 anti-Dsg1 autoantibodies are capable of eliciting
experimental PF Because IgG1 is the only isotype of anti-
Dsg1 autoantibodies in these PF patients and it binds mouse skin
(Fig 1H), it was of interest to know whether the IgG1 can elicit
experimental PF. To assess the pathogenic activity of IgG1
autoantibodies in vivo, a mouse passive transfer model was
utilized as described (Arteaga et al, 2002). Because we only have
enough serum samples from two of these four PF patients,
passive transfer experiments were performed using a⁄nity-
puri¢ed autoantibodies from their samples and used to assess the
pathogenic activities of their IgG1 autoantibodies. Both patients’
autoantibodies elicited disease in neonatal mice. As demonstrated
in Fig 2(A), IgG autoantibodies from a representative patient
successfully induced skin lesions in neonatal mice with clinical,
histologic, and immunologic features similar to those observed
in human patients with PF, indicating that IgG1 anti-Dsg1
autoantibodies in this subset of patients are as e¡ective in
inducing experimental PF as IgG4 autoantibodies from other PF
patients (Rock et al, 1989). The autoantibody-induced skin lesions
in experimental PF were abolished by preabsorbing patients’ IgG
with equal quantity of rDsg1 (Fig 2B), but not rDsg3 (Fig 2C),
further con¢rming the fact that IgG1 anti-Dsg1 autoantibodies
caused super¢cial blisters in these patients.
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IgG1 anti-Dsg1 autoantibodies recognize a conformational
epitope in the N-terminus of Dsg1 To analyze the
conformational epitope(s) recognized by the IgG1 anti-Dsg1
autoantibodies from these patients, rDsg1, rDsg3, and domain-
swapped Dsg proteins were used in the competition Dsg1
ELISA (Sekiguchi et al, 2001). As shown in Fig 3(A), rDsg1, but
not rDsg3, inhibited the activity of anti-Dsg1 in a concentration-
dependent manner. To further determine the location of
epitope(s) recognized by IgG1 anti-Dsg1 autoantibodies,
domain-swapped Dsg proteins were used in the competition
ELISA. As shown in Fig 3(B), the anti-Dsg1 activity of a
representative PF patient was blocked by domain-swapped
proteins Dsg11^161/Dsg3163^566 and Dsg11^401/Dsg3405^566 in a
concentration-dependent manner, but not by Dsg31^161/Dsg1164^
496 or Dsg31^403/Dsg1404^496. At a concentration of 5 mg/mL,
both Dsg11^161/Dsg3163^566 and Dsg11^401/Dsg3405^566 were able
to inhibit the activity of IgG1 anti-Dsg1 by 100% in the Dsg1
ELISA. Because the antigen-binding activities of anti-Dsg1
autoantibodies were inhibited by Dsg11^161/Dsg3163^566 and
Dsg11^401/Dsg3405^566, but not by Dsg31^161/Dsg1164^496, our
results suggested that the Dsg1 epitope(s) recognized by IgG1
anti-Dsg1 autoantibodies from this subset of PF patients is
located on the ¢rst 161 amino acids of the Dsg1. To further
investigate whether the conformational epitopes recognized by
IgG anti-Dsg1 autoantibodies are located at the N-terminus of
Dsg1, Dsg11^87/Dsg387^566 and Dsg31^88/Dsg189^496 were used in
the competition Dsg1 ELISA. As demonstrated in Fig 3(C), the
activity of anti-Dsg1 autoantibodies was blocked by Dsg11^87/
Dsg387^566 (but not by Dsg31^88/Dsg189^496), following a
concentration-dependent pattern, supporting the fact that the
conformational epitopes recognized by IgG1 anti-Dsg1 auto-
antibodies are located at the N-terminus of Dsg1.
IgG1 anti-Dsg1 autoantibodies recognize linear epitopes on
the ectodomain of Dsg1 Previously, it was shown that IgG1
anti-Dsg1 autoantibodies from PF patients also recognize a linear
epitope(s) (Emery et al, 1995; Hacker et al, 2002). To determine
whether these four PF patients also had anti-Dsg1 that
recognized the linear Dsg1 epitope(s), IB was performed. As
demonstrated in Fig 4(A), autoantibodies from these PF patients
only recognized rDsg1, but not rDsg3, by IB, suggesting that
anti-Dsg1 from this subset of PF patients also bound the linear
epitope(s) on the ectodomain of Dsg1. There were no other IgG
subclass autoantibodies that recognized rDsg1 by IB except IgG1
(Fig 4B); these results further con¢rmed that IgG1 was the sole
isotype of anti-Dsg1 in these patients. To further identify
whether anti-Dsg1 autoantibodies against linear Dsg1 epitopes
are independent from those recognizing conformational
epitopes, IB against rDsg1 was performed using serum
preabsorbed with either rDsg1 or rDsg3. As shown in Fig 4C,
serum samples at a dilution of 1:100 preabsorbed with 5 mg of
rDsg1, although lost activity to rDsg1 in ELISA (Fig 3),
continued to react with denatured rDsg1 in IB. These results
suggested that autoantibodies recognizing linear Dsg1 epitopes
are distinct from those binding to conformational epitopes.
Figure1. IgG1 PF patients exhibit IgG1, but not IgG4, autoantibodies that cross-react with murine skin. To investigate the isotype pro¢le of
autoantibodies of this subset of PF patients, indirect IF was performed using tissues from monkey esophagus (A^C), adult human skin (D^F), and neonatal
mouse skin (G^I). Serum of this patient at a dilution of 1:20 was used in this assay. Mouse anti-human-IgG (A,D,G), -IgG1 (B,E,H), and -IgG4 (C,F,I)
conjugated with FITC were used as the secondary antibodies in this assay. Data from a representative patient are shown here.
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Upon identi¢cation of the linear Dsg1 epitope(s), we found that
serum from these patients bound fusion proteins spread
throughout the extracellular domain of Dsg1 (Table I; Fig 4D).
No common linear epitopes among these four PF patients could
be identi¢ed by the IB studies. Along with the indirect IF and
ELISA results, these ¢ndings suggest that there were two popu-
lations of IgG1 anti-Dsg1 autoantibodies in this unique subset of
PF patients, one recognizing a conformational, while the other
binding to the linear epitope(s) on the ectodomain of Dsg1.
DISCUSSION
IgG1 and IgG4 are the two predominant isotypes of autoantibo-
dies in patients with pemphigus; nevertheless, the clinical and im-
munologic implications of the dual isotypes of anti-Dsg are not
yet clear. In pemphigus vulgaris, distinct epitopes are recognized
by these two isotypes of anti-Dsg3 (Bhol et al, 1995). It was sug-
gested that IgG4 anti-Dsg3 is directly linked to the activity of the
disease (Bhol et al, 1994). In a recent study of the endemic PF in
Brazil, it was also demonstrated that IgG1 anti-Dsg1 is associated
with the remission of the disease, whereas the IgG4 isotype of
autoantibodies is closely related to the activity of PF (Warren
et al, 2003). Although, IgG1 anti-Dsg1 autoantibodies could be
readily identi¢ed in endemic PF patients before the onset of their
disease (Lin et al, 2001), the pathophysiologic role of IgG1 anti-
Dsg1 autoantibodies in these individuals is still elusive. From this
previous study, it is clear that IgG1 anti-Dsg1 autoantibodies from
normal individuals recognize denatured rDsg1 by IB and bind
tissues only from monkey esophagus but not tissues from human
or murine skin by indirect IF; nevertheless, the epitope speci¢city
of these autoantibodies is not clear. Moreover, puri¢ed anti-Dsg1
autoantibodies from a normal individual failed to induce disease
in the passive transfer experiments, suggesting that IgG1 anti-
Dsg1 from normal individuals in the endemic PF areas may not
play a direct role in the development of the disease.
Recently, we reported that IgG1 and IgG4 anti-Dsg1 in PF pa-
tients demonstrated distinct tissue and epitope speci¢city (Hacker
et al, 2002). It appears that anti-Dsg1 autoantibodies of the IgG1
isotype recognize both linear and conformational epitope(s) and
fail to bind mouse skin, while its IgG4 counterpart recognizes
only a conformational epitope(s) but can bind mouse skin. This
¢nding suggests that the inability of IgG1 anti-Dsg1 to elicit the
experimental PF in neonatal mice is simply because this isotype
of autoantibodies in some PF patients does not cross-react with
mouse skin, but not due to a lower pathogenicity of the autoan-
tibodies of this isotype or an insu⁄cient amount of autoantibo-
dies used in previous studies (Rock et al, 1989).
In this report, we identi¢ed a unique subset of PF patients who
only express IgG1 anti-Dsg1 autoantibodies throughout the
Figure 2. IgG1 anti-Dsg1 autoantibodies from PF patients are pathogenic in the passive transfer animal model. To test whether IgG1 autoanti-
bodies from this subset of PF patients are able to elicit experimental PF, neonatal BALB/c mice were injected with 1 mg per g protein G column-puri¢ed
autoantibodies (A). Eighteen hours after antibody injection, skins of the neonatal mice were examined for clinical, histologic, and immunologic features of
PF. Mice received IgG autoantibodies from this patient developed Nikolsky’s sign upon physical examination (top). Biopsies taken from these mice demon-
strated intraepidermal blister formation resembling human PF lesions (middle), and the deposition of human autoantibodies can be detected by direct IF
study (bottom). Mice that received IgG from normal volunteers did not develop experimental PF (not shown). The arrows indicate the super¢cial blister
induced by autoantibodies (top) or direct deposit of autoantibodies (bottom). To verify that the PF-like lesions observed in the passive transfer experiments
are indeed mediated by anti-Dsg1 autoantibodies, equal amounts of rDsg1 (B) or rDsg3 (C) were ¢rst incubated with protein G-puri¢ed IgG from PF
patients before injecting to neonatal mice. Preincubation of IgG autoantibodies with rDsg1 clearly blocked the development of skin lesions and formation
of super¢cial blister (B), whereas mice that received IgG preincubated with rDsg3 continued to develop experimental PF (C). Data from one of two IgG1PF
patients are shown here.
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course of their disease. This conclusion was drawn based on the
observation that both direct and indirect IF microscopy and Dsg1
ELISA only detect IgG1 anti-Dsg1 in samples collected from these
four patients. Our ¢ndings are clearly di¡erent from those re-
ported previously, which demonstrated that IgG4 is the predomi-
nant isotype of anti-Dsg1 in patients with PF (Futei et al, 2001;
Warren et al, 2003). Interestingly, this subset of patients does not
express distinct clinical features as those PF patients producing
both IgG1 and IgG4 anti-Dsg1 autoantibodies. Assessing the
pathogenicity of autoantibodies using a passive transfer animal
model, we demonstrated that the IgG1 anti-Dsg1 autoantibodies
from these patients were capable of eliciting PF-like lesions in
neonatal mice (Fig 2), providing the ¢rst evidence that this sub-
class of anti-Dsg1 is able to induce experimental PF in the passive
transfer model. Comparing the clinical, histologic, and immuno-
logic features in the experimental PF mice induced by IgG1 anti-
Dsg1 autoantibodies, there is no noticeable di¡erence from those
elicited by IgG4 autoantibodies from patients with endemic PF
(Rock et al, 1989).
Because IgG1 and IgG4 anti-Dsg1 autoantibodies from patients
with PF exhibit distinct tissue and antigen-binding speci¢city
(Hacker et al, 2002), we speculate that anti-Dsg1 from these IgG1
PF patients may recognize unique Dsg1 epitope(s). Nevertheless,
from the competition ELISA using domain-swapped Dsg pro-
teins, we found that IgG1 autoantibodies from these patients ap-
pear to recognize similar if not the same conformational
epitope(s) (i.e., the ¢rst 87 amino acids of Dsg1 ectodomain)
(Fig 3) as those of other PF patients (Sekiguchi et al, 2001). This
¢nding along with the previous report supports the conclusion
that the N-terminus of Dsg1 harbors key epitope(s) that are criti-
cal for the development of PF (Amagai et al, 1995; Kowalczyk
et al, 1995; Sekiguchi et al, 2001).
Figure 3. Autoantibodies from IgG1 PF patients recognize a confor-
mational epitope(s) on the N-terminus of Dsg1. To analyze the con-
formational epitope(s) recognized by IgG1 autoantibodies from this group
of PF patients, competition Dsg1 ELISAwas employed. Serum samples of
these patients were ¢rst incubated with various concentrations of rDsg1 or
rDsg3 (A) or Dsg domain-swapped proteins (B,C) for 1 h at room tempera-
ture before the determination of anti-Dsg1 activity by Dsg1 ELISA. The
recombinant proteins that inhibited the antigen-binding activity of anti-
Dsg1 autoantibodies were considered harboring the epitope(s). The data
are expressed as percentages of binding inhibition of autoantibodies to
Dsg1 in ELISA. Data from a representative PF patient are presented here.
Figure 4. IgG1 anti-Dsg1 autoantibodies from IgG1 PF patients
recognize linear epitopes on the ectodomain of Dsg1.To analyze the
IgG autoantibody activity of these patients, IB assays were performed using
rDsg1 (lane 1) and rDsg3 (lane 2) (A). The subclass autoantibodies against
rDsg1 were identi¢ed using HRP-conjugated mouse anti-human IgG1
(lane 1), -IgG2 (lane 2), -IgG3 (lane 3), and -IgG4 (lane 4) (B). To identify
whether anti-Dsg1 against linear Dsg1 epitopes are distinct from those re-
acting with conformational epitopes, serum at a dilution of 1:100 was ¢rst
incubated with bu¡er (lane 1) or 5 mg of rDsg1 (lane 2) or rDsg3 (lane 3)
before IB experiments (C). The detailed linear epitopes recognized by
IgG1 anti-Dsg1 autoantibodies from these patients were analyzed using re-
combinant GST fusion proteins encompassing the ectodomain of Dsg1
(D). Lane 1, GST; lane 2, Dsg1.1; lane 3, Dsg1.2; lane 4, Dsg1.3; lane 5,
Dsg1.4; lane 6, Dsg1.5; lane 7, Dsg1.6; lane 8, Dsg1.7; lane 9, Dsg1.8; lane 10,
Dsg1.9; lane 11,Dsg1.10; and lane 12,Dsg1.11. The arrows indicate the location
of rDsg1. Molecular weight marker is marked on the left-hand side of each
¢gure. Data from a representative PF patient are demonstrated here.
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In this subset of PF patients, we also found that the IgG1 anti-
Dsg1 autoantibodies reacted with linear epitopes (Fig 4A,B). In-
terestingly, serum samples from these patients maintained activity
to denatured rDsg1 after preabsorption with rDsg1 in Ca2þ -
abundant bu¡er (Fig 4C), suggesting that there are two popula-
tions of autoantibodies in these PF patients, one recognizing the
conformational epitopes and the other binding the linear epi-
topes. A detailed epitope mapping study revealed that the linear
Dsg1 epitopes were not limited to the N-terminus of Dsg1 (Fig
4D). It appears that the linear epitopes recognized by IgG anti-
Dsg1 of these patients are spread out along the ectodomain of
Dsg1 (Table I). From the four PF patients tested here, along with
a previous report (Arteaga et al, 2000), no common Dsg1 linear
epitopes recognized by PF autoantibodies could be identi¢ed.
When the binding activities of anti-Dsg1 autoantibodies to Dsg1
fusion proteins were removed by preabsorption, the serum sam-
ples continued to react with Dsg1 by ELISA and indirect IF (not
shown). It is possible that the production of autoantibodies to lin-
ear Dsg1 epitopes in PF patients is an epi-phenomenon of auto-
immune responses developed from the destruction of epidermis
induced by pathogenic anti-Dsg1 and the subsequent exposure
of epitopes on the ectodomain of Dsg1 that are inaccessible to
the autoimmune reaction. The relationship of these linear epi-
topes to the development of disease is unknown.
In conclusion, we found that IgG1 anti-Dsg1 autoantibodies
from this particular subset of PF patients share similar properties
to those of IgG4 anti-Dsg1 autoantibodies from other PF patients.
This includes the induction of experimental PF in the passive
transfer animal model and binding both human and mouse skin.
Unlike IgG4 anti-Dsg1, which does not bind the denatured form
of Dsg1, IgG1 autoantibodies from these patients did react with
the Dsg1 ectodomain by IB. At present, it is not clear what me-
chanism(s) governs the production of only IgG1, but not IgG4,
autoantibodies that recognize the linear epitopes on Dsg1 in PF
patients. Our identi¢cation of this unique subset of PF patients
expressing only pathogenic IgG1 autoantibodies throughout the
course of their disease further illustrates the complexity of auto-
immune response in PF. Furthermore, the demonstration of the
pathogenic IgG1 antibodies in PF suggests that the IgG subclass
does not necessarily determine the epitopes and pathogenicity of
pemphigus autoantibodies.
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Table I. IgG1 anti-Dsg1 autoantibodies recognize linear epitopes on the ectodomain of Dsg1a
Patient
IgG1 anti-Dsg1 autoantibody
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 1.10 1.11
PF1 þ (^) (^) (^) þ þ (^) (^) þ (^) þ
PF2 (^) (^) (^) (^) (^) (^) (^) þ (^) þ (^)
PF3 (^) þ (^) (^) (^) (^) (^) (^) (^) (^) þ
PF4 (^) (^) þ (^) (^) (^) (^) (^) (^) þ (^)
aTo determine the linear epitope(s) recognized by anti-Dsg1 from PF patients expressing only IgG1 autoantibodies, IB assay was performed as described under Materials
and Methods. A Dsg1 fragment that was bound by autoantibodies was recognized as harboring an anti-Dsg1 epitope(s) and marked as ‘‘þ ’’; a fragment that was not bound
by autoantibodies was considered negative for anti-Dsg1 epitope and marked as ‘‘(^).’’
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